Key Biologics teams with CRBS as cell-based therapeutics drive demand for blood products

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Moussa81)
(Image: Getty/Moussa81)

Related tags: cell and gene therapy, Blood, Research and development, biospecimen

Key Biologics and Cascade Regional Blood Services’ multi-year agreement will provide researchers with the critical raw material needed for developing cell- and gene-based therapies.

Edward Scott, MD, chief medical officer, Key Biologics (Key), told us the company has provided research- and clinical-grade human cells and blood products to the industry from its Memphis site for years, but needed to expand its reach to include other metropolitan areas.

Cascade Regional Blood Services (CRBS) is a not-for-profit independent blood center serving Western Washington. CRBS also is a member of Blood Centers of America (BCA), which Key in September 2018 entered into an agreement with to leverage each organization’s resources.

Scott said the company’s location in the Seattle/Tacoma area will provide a larger metropolitan area for recruiting donors and provides “enhanced opportunities for shipment of collected products into Asia and Australia.”

“Timely deliver of products to those areas from Memphis is very problematic,”​ he said – though a location in Tacoma will allow faster and less expensive delivery options for customers on the West Coast.

The partnership will focus on collecting mononuclear cells (MNCs) by leukapheresis and includes joint donor recruitment, product distribution, and marketing, Scott explained.

“With this partnering opportunity, CRBS can offer their base of volunteer donors new ways to help support medical care and research,”​ he added. “Customers benefit by having access to an increased supply of raw materials and the ability to collect products from a larger and more diverse base of donors.”

The demand for human blood cells

The recent success of cell-based therapeutics in the clinic and on the market is driving demand for the critical raw materials needed for development.

“It is now clear that allogeneic and autologous cellular therapies can offer new therapies for diseases for which there are currently no effective alternatives,”​ said Scott.

Increased academic research in these areas also has driven a steady increase in the transfer of intellectual property (IP) to early-stage companies, he added, and these companies need access to cells.

“We expect that the demand for human blood cells as raw material will only continue to increase,”​ Scott said. “Key and CRBS have taken an early position in this growing field of science.”

Additionally, Key in August 2018 merged with Astarte Biologic – which also has a long-standing relationship with CRBS – adding complementary immunology expertise and expanded capabilities. 

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Related suppliers

Follow us

Products

View more

Webinars